Glenmark Pharmaceuticals has received final approval from the US health regulator for Desonide lotion used to treat skin rashes and irritation.
“Glenmark Pharmaceuticals has been granted final approval by the United States Food and Drug Administration (USFDA) for Desonide lotion, 0.05 per cent,” the company said in a regulatory filing today.
According to IMS health sales data, for the 12 months ended July, the Desonide lotion, 0.05 per cent, achieved annual sales of around $23.2 million, Glenmark said.
The company’s current portfolio consists of 126 products authorised for distribution in the US market and 61 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added.
Shares of Glenmark Pharmaceuticals were trading down by 0.13 per cent at Rs 612 on the BSE.